Related Experiment Video
Updated: Oct 5, 2025
10:04
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
10.9K
Current Frontline Treatment of Diffuse Large B-Cell Lymphoma
Michael A Spinner1, Ranjana H Advani1
1Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford, CA.
Oncology (Williston Park, N.Y.)
|January 28, 2022
Summary
New treatments like polatuzumab vedotin (Polivy) show promise for diffuse large B-cell lymphoma (DLBCL). Research is ongoing to personalize therapy for aggressive B-cell lymphomas, improving outcomes beyond standard R-CHOP.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Diffuse large B-cell lymphoma (DLBCL) is an aggressive, heterogeneous non-Hodgkin lymphoma.
- Current standard treatment, R-CHOP, cures over 60% but novel agents are needed for resistant disease.
- Risk stratification relies on factors like International Prognostic Index and molecular subsets.
Purpose of the Study:
- To review current DLBCL treatment standards and emerging therapies.
- To highlight advancements in risk stratification and personalized medicine for DLBCL.
- To discuss the potential of novel agents and response-adapted strategies.
Main Methods:
- Review of current clinical practice and recent clinical trial data.
- Analysis of emerging therapeutic strategies including antibody-drug conjugates and cellular therapies.
- Discussion of advanced diagnostic and prognostic markers like PET metrics and ctDNA.
Main Results:
- The POLARIX trial suggests polatuzumab vedotin (Polivy) plus R-CHP improves progression-free survival over R-CHOP.
- Frontline therapies integrating novel agents show promising preliminary results.
- Personalized approaches using molecular subsets and dynamic risk assessments are under investigation.
Conclusions:
- Polatuzumab vedotin-based therapy may become a new standard for eligible DLBCL patients.
- Further research is essential to define optimal personalized treatment strategies for DLBCL.
- Integrating novel agents and response-adapted therapy holds potential to improve outcomes in DLBCL.
More Related Videos
Related Concept Videos
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
02:57Targeted Cancer Therapies
7.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.9K
02:50Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
01:27Tumor Immunotherapy
711
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
711
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
235
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
235
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
249
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
249